Add to Favourites
To login click here
This study uses a three-step approach to discover, validate, and deliver a highly performing, blood-based epigenetic biosignature of diagnostic clinical value in schizophrenia. Through an AutoML-aided, data-driven biomarker discovery approach, specific gene methylation biomarkers were identified and investigated for their biological relevance to known schizophrenia pathophysiological pathways. The study utilized publicly available DNA methylation data from schizophrenia patients and healthy individuals to establish specific disease biosignatures.